Crizotinib is a first generation tyrosine kinase inhibitor for ALK gene positive nonsmall cell lung cancer (ALK + NSCLC). The FDA approved its use in 2011. 1 There has been a recent recognition of crizotinib-associated renal cysts (CARCs). READ ARTICLE
Urology DOI:10.1016/j.urology.2019.04.035
Authors: Christine W. Liaw, Michael Palese, Larry Di Fabrizio
